QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:IOBT

IO Biotech - IOBT News Today

$2.65
-0.05 (-1.85%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.53
$2.95
50-Day Range
$2.30
$3.02
52-Week Range
$2.15
$9.77
Volume
70,123 shs
Average Volume
120,963 shs
Market Capitalization
$76.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.


IOBT Media Mentions By Week

IOBT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IOBT
News Sentiment

0.00

0.46

Average
Medical
News Sentiment

IOBT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IOBT Articles
This Week

0

0

IOBT Articles
Average Week

SourceHeadline
markets.businessinsider.com logoMorgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)
markets.businessinsider.com - January 24 at 1:00 PM
finance.yahoo.com logoIO Biotech Announces Appointment of Devin Smith as General Counsel
finance.yahoo.com - January 23 at 10:46 AM
finance.yahoo.com logoIO Biotech Provides Business Update
finance.yahoo.com - January 9 at 7:55 AM
finance.yahoo.com logoAnalyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
finance.yahoo.com - November 21 at 6:10 PM
finance.yahoo.com logoIO Biotech Announces Third Quarter Results for 2022
finance.yahoo.com - November 9 at 9:22 PM
finance.yahoo.com logoIO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
finance.yahoo.com - November 9 at 9:22 PM
finance.yahoo.com logoIO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
finance.yahoo.com - November 3 at 11:35 AM
finance.yahoo.com logoIO Biotech to Participate in the Jefferies London Healthcare Conference
finance.yahoo.com - October 31 at 9:39 AM
businesswire.com logoAurion Biotech Wins Prestigious Prix Galien Startup Award
businesswire.com - October 30 at 12:06 AM
finance.yahoo.com logoIs IO Biotech (NASDAQ:IOBT) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - October 15 at 1:32 PM
finance.yahoo.com logoIO Biotech Announces Appointment of New Chief Financial Officer
finance.yahoo.com - October 13 at 5:48 PM
finance.yahoo.com logoIO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
finance.yahoo.com - October 5 at 10:07 AM
finance.yahoo.com logoIO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
finance.yahoo.com - September 6 at 8:27 AM
finance.yahoo.com logoIO Biotech Announces Second Quarter Results for 2022
finance.yahoo.com - August 11 at 8:17 PM
seekingalpha.com logoInotiv, IO Biotech top healthcare gainers; Regulus, Aerovate lead losers' pack
seekingalpha.com - July 19 at 11:01 PM
finance.yahoo.com logoIO Biotech to Participate in the 2022 BIO International Convention
finance.yahoo.com - June 6 at 8:58 AM
finance.yahoo.com logoIO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
finance.yahoo.com - May 26 at 9:18 PM
finance.yahoo.com logoIO Biotech to Participate in the Jefferies Healthcare Conference
finance.yahoo.com - May 23 at 6:10 PM
finance.yahoo.com logoIO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
finance.yahoo.com - May 18 at 11:28 AM
finance.yahoo.com logoIO Biotech Announces First Quarter Results for 2022
finance.yahoo.com - May 16 at 5:26 PM
finance.yahoo.com logoWe're Not Very Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
finance.yahoo.com - May 8 at 8:27 AM
finance.yahoo.com logoIO Biotech Hosting Key Opinion Leader Webinar Series
finance.yahoo.com - April 22 at 8:45 AM
seekingalpha.com logoIO Biotech begins mid-stage trial of NSCLC candidate IO102-IO103
seekingalpha.com - April 12 at 6:16 PM
finance.yahoo.com logoIO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial
finance.yahoo.com - April 12 at 9:55 AM
finance.yahoo.com logoIO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
finance.yahoo.com - April 11 at 5:08 PM
investing.com logoIO Biotech Inc (IOBT)
investing.com - April 10 at 5:08 AM
seekingalpha.com logoIO Biotech posts positive data from metastatic melanoma therapy trial
seekingalpha.com - April 8 at 5:44 PM
finance.yahoo.com logoIO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting
finance.yahoo.com - April 8 at 5:44 PM
seekingalpha.com logoIO Biotech reports FY results
seekingalpha.com - March 31 at 6:41 PM
seekingalpha.com logoSUNW, CEI and HNRG among mid-day movers
seekingalpha.com - March 9 at 10:24 AM
finance.yahoo.com logoIO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022
finance.yahoo.com - March 8 at 7:47 PM
finance.yahoo.com logoIO Biotech Announces Appointment of David V. Smith to its Board of Directors
finance.yahoo.com - March 3 at 6:01 PM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)?
finance.yahoo.com - February 7 at 8:54 AM
nasdaq.com logoCould The IO Biotech, Inc. (NASDAQ:IOBT) Ownership Structure Tell Us Something Useful?
nasdaq.com - February 5 at 1:59 PM
finance.yahoo.com logoIO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
finance.yahoo.com - December 9 at 1:28 PM
finance.yahoo.com logoIO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
finance.yahoo.com - December 6 at 8:41 AM
nasdaq.com logoIO Biotech Trading 21% Higher
nasdaq.com - December 3 at 3:00 PM
realmoney.thestreet.com logoIO Biotech, Inc. (IOBT)
realmoney.thestreet.com - December 2 at 11:55 PM
Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:IOBT) was last updated on 2/6/2023 by MarketBeat.com Staff